Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study

Reproductive Biology and Endocrinology

Massimo Moscarini¹  Roberto Marci²  Valeria Raparelli⁴  Donatella Caserta¹  Elena Vaquero⁶  Claudio Manna⁵  Roberta Poverini³  Rosella Lisi³  Rocco Rago³  Mario Montanino Oliva³  Piero Carfagna³  Franco Lisi³ 

[1] Department of Women Health and Territorial Medicine, Sapienza - University of Rome, Sant’Andrea Hospital, Rome, Italy;Department of Biomedical Sciences and Advanced Therapies, Section of Obstetrics and Gynecology, University Hospital of Ferrara, Ferrara, Italy;Center for Reproductive Medicine Research, Clinica Villa Mafalda, Rome, Italy;Department of Internal Medicine and Medical Specialties, Sapienza - University of Rome, Rome, Italy;GENESIS Center for Reproductive Medicine, Rome, Italy;Department of Surgery, Tor Vergata - University of Rome, Rome, Italy

关键词: Embryos;    Oocytes;    ICSI;    IVF;    Stimulation;    Follicle;    Inositol;    Myo-inositol;   

Others  :  1150496
DOI  :  10.1186/1477-7827-10-52

 received in 2012-04-14, accepted in 2012-07-09,  发布年份 2012

【 摘 要 】

Background

Aim of this pilot study is to examine the effects of myo-inositol administration on ovarian response and oocytes and embryos quality in non PolyCystic Ovary Syndrome (PCOS) patients undergoing multiple follicular stimulation and in vitro insemination by conventional in vitro fertilization or by intracytoplasmic sperm injection.

Methods

One hundred non-PCOS women aged <40 years and with basal FSH <10 mUI/ml were down-regulated with triptorelin acetate from the mid-luteal phase for 2 weeks, before starting the stimulation protocol for oocytes recovery. All patients received rFSH, at a starting dose of 150 IU for 6 days. The dose was subsequently adjusted according to individual response. Group B (n = 50) received myo-inositol and folic acid for 3 months before the stimulation period and then during the stimulation itself. Group A (n-50) received only folic acid as additional treatment in the 3 months before and through treatment.

Results

Total length of the stimulation was similar between the two groups. Nevertheless, total amount of gonadotropins used to reach follicular maturation was found significantly lower in group B. In addition, the number of oocytes retrieved was significantly reduced in the group pretreated with myo-inositol. Clinical pregnancy and implantation rate were not significantly different in the two groups.

Conclusions

Our findings suggest that the addition of myo-inositol to folic acid in non PCOS-patients undergoing multiple follicular stimulation for in-vitro fertilization may reduce the numbers of mature oocytes and the dosage of rFSH whilst maintaining clinical pregnancy rate. Further, a trend in favor of increased incidence of implantation in the group pretreated with myo-inositol was apparent in this study. Further investigations are warranted to clarify this pharmacological approach, and the benefit it may hold for patients.

【 授权许可】

   
2012 Lisi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kane MT: The effects of water-soluble vitamins on the expansion of rabbit blastocysts in vitro. J Exp Zool 1988, 245:220-223.
• [2]Berridge MJ: Inositol lipids and cell proliferation. Biochim Biophys Acta 1987, 907:33-45.
• [3]Downes CP: Twenty-fifth Colworth medal lecture. The cellular functions of myo-inositol. Biochem Soc Trans 1989, 17:259-268.
• [4]Akiba S, Sato T: Cellular function of calcium-independent phospholipase A2. Biol Pharm Bull 2004, 27:1174-1178.
• [5]Aouameur R, Da Cal S, Bissonnette P, Coady MJ, Lapointe JY: SMIT2 mediates all myo-inositol uptake in apical membranes of rat small intestine. Am J Physiol Gastrointest Liver Physiol 2007, 293:G1300-1307.
• [6]Smith SD, Mikkelsen A, Lindenberg S: Development of human oocytes matured in vitro for 28 or 36 hours. Fertil Steril 2000, 73:541-544.
• [7]Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ: Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002, 17:1591-1596.
• [8]Papaleo E, Unfer V, Baillargeon JP, Chiu TT: Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol 2009, 147:120-123.
• [9]Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L: myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009, 91:1750-1754.
• [10]Larner J: Mediators of postreceptor action of insulin. Am J Med 1983, 74:38-51.
• [11]Saltiel AR: Second messengers of insulin action. Diabetes Care 1990, 13:244-256.
• [12]Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G: Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999, 340:1314-1320.
• [13]Cheang KI, Baillargeon JP, Essah PA, Ostlund RE, Apridonize T, Islam L, Nestler JE: Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008, 57:1390-1397.
• [14]Azziz R: PCOS: a diagnostic challenge. Reprod Biomed Online 2004, 8:644-648.
• [15]Baillargeon JP, Iuorno MJ, Nestler JE: Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003, 46:325-340.
• [16]Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, Apridonidze T, Iuorno MJ, Nestler JE: Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006, 29:300-305.
• [17]Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE: Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002, 8:417-423.
• [18]Unfer V, Carlomagno G, Dante G, Facchinetti F: Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012, 28(7):509-515.
• [19]Carlomagno G, Unfer V: Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci , 15:931-936.
• [20]Fishel S, Lisi F, Rinaldi L, Green S, Hunter A, Dowell K, Thornton S: Systematic examination of immobilizing spermatozoa before intracytoplasmic sperm injection in the human. Hum Reprod 1995, 10:497-500.
• [21]Veeck LL: Atlas of the Human Oocyte and early conceptus. Williams & Wilkins, Baltimore; 1986.
• [22]Baillargeon JP, Nestler JE, Ostlund RE, Apridonidze T, Diamanti-Kandarakis E: Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod 2008, 23:1439-1446.
• [23]Costantino D, Minozzi G, Minozzi E, Guaraldi C: Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009, 13:105-110.
• [24]Ciotta L, Stracquadanio M, Pagano I, Carbonaro A, Palumbo M, Gulino F: Effects of inositol on oocyte quality in patients affected with polycystic ovary syndrome. Minerva Ginecol 2010, 62:525-531.
• [25]Fahy MM, Kane MT: Incorporation of [3 H] inositol into phosphoinositides and inositol phosphates by rabbit blastocysts. Mol Reprod Dev 1993, 34:391-395.
• [26]Holm P, Booth PJ, Schmidt MH, Greve T, Callesen H: High bovine blastocyst development in a static in vitro production system using SOFaa medium supplemented with sodium citrate and myo-inositol with or without serum-proteins. Theriogenology 1999, 52:683-700.
• [27]Berridge MJ, Irvine RF: Inositol phosphate and cell signalling. Nature 1989, 306:197-205.
• [28]Chiu TT, Tam PP: A correlation of the outcome of clinical in vitro fertilization with the inositol content and embryotrophic properties of human serum. J Assist Reprod Genet 1992, 9:524-530.
• [29]Groenen PM, Merkus HM, Sweep FC, Wevers RA, Janssen FS, Steegers-Theunissen RP: Kinetics of myo-inositol loading in women of reproductive age. Ann Clin Biochem 2003, 40:79-85.
• [30]Jedrusik A, Ajduk A, Pomorski P, Maleszewski M: Mouse oocytes fertilised by ICSI during in vitro maturation retain the ability to be activated after refertilisation in metaphase II and can generate Ca2+ oscillations. BMC Dev Biol 2007, 7:72. BioMed Central Full Text
• [31]Chiu TT, Rogers MS, Briton-Jones C, Haines C: Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum Reprod 2003, 18:408-416.
• [32]Kurokawa M, Fissore RA: ICSI-generated mouse zygotes exhibit altered calcium oscillations, inositol 1,4,5-trisphosphate receptor-1 down-regulation, and embryo development. Mol Hum Reprod 2003, 9:523-533.
• [33]Fulka J, First NL, Moor RM: Nuclear and cytoplasmic determinants involved in the regulation of mammalian oocyte maturation. Mol Hum Reprod 1998, 4:41-49.
• [34]Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe GP, Picconeri MG, Campbell A: Use of recombinant LH in a group of unselected IVF patients. Reprod Biomed Online 2002, 2(5):104-108.